A federal judge has made the decision to extend an order blocking the National Institutes of Health (NIH) from reducing grant funding to institutions conducting medical and scientific research. This decision comes after Judge Angel Kelley of the Federal District Court for the District of Massachusetts temporarily halted the Trump administration’s cuts from taking effect earlier this month. The hold on the cuts was set to expire on Monday, prompting an urgent hearing on Friday to address the issue more permanently.
The lawsuit revolves around the NIH’s proposal to cut around $4 billion in grants for “indirect costs,” which are described as tangential expenditures for facilities and administrators. The NIH argues that these funds could be better spent directly funding research and has proposed reducing funding for indirect costs to a 15 percent rate for all institutions receiving funds.
However, lawyers representing states and research institutions have argued that direct and indirect costs are often intertwined. They presented scenarios where both types of costs are essential for research to take place, such as the example of a researcher conducting experiments funded by an NIH grant and a worker disposing of hazardous waste produced by those experiments. Both roles are crucial for the research to progress, yet one is classified as a direct cost and the other as an indirect cost.
The plaintiffs’ lawyers highlighted the potential adverse effects of the funding cuts, including the possibility of layoffs for highly skilled staff members like veterinary technicians and hospital nurses. They also warned of paused clinical trials on new drugs and the inability of institutions to rehire employees once experiments and trials are halted.
On the other hand, the government’s lawyer, Brian Lee, argued that the effects mentioned by the plaintiffs were speculative and did not constitute irreparable harm. He suggested that the plaintiffs could seek other means of recovering lost funding, such as suing under the Tucker Act.
The debate also touched on the arbitrary nature of capping indirect funds at 15 percent across the board. The plaintiffs’ lawyers argued that institutions of different sizes have varying needs when negotiating with the government, and forcing all to adapt to a 15 percent maximum was unreasonable. They emphasized the importance of considering economies of scale, where larger institutions can house multiple projects within one building, affecting their ratio of direct and indirect costs.
The outcome of this lawsuit will have far-reaching implications for research institutions and the future of medical and scientific research in the United States. As the legal battle continues, the fate of crucial research projects, clinical trials, and the livelihoods of highly skilled staff members hang in the balance.
